The goal is to investigate brain systems that mediate cognitive, affective, and reward? processing in humans and to determine how these systems are influenced by late life depression, by? genetic risk factors associated with depression, and by experimental manipulations of serotonin? levels. Behavioral challenge tasks will be use during functional magnetic resonance imaging (fMRI) to? investigate four specific aims: (1) We will complete studies initiated in the current funding period that? investigate the influence of vascular lesions upon the interaction of ventral systems for emotional? regulation and dorsal systems for executive control in patients with late life depression. These? on-going studies also include an assessment of current clinical status, and whether treatment has? led to a remission from depression. (2) We will characterize genetic influences upon the neural? processing of emotional and rewarding stimuli using a task developed in current period that? measures activity in amygdala, ventromedial and orbital frontal cortex, and ventral frontal cortex, and a? second task that measures activity in striatal, midbrain, and dorsal systems associated with? decisions about rewards. (3) We will evaluate the effects of neurotransmitter levels upon the neural? processing of emotional and rewarding stimuli. Neuroimaging and neurophysiological studies? reveal correlations between measures of neuronal activity and measures of behavioral states (e.g.,? mood, decision preference, response time). Such correlations suggest functional relationships, but? typically remain untested. To functionally probe the effects of emotional/reward systems upon? executive processing systems, we will pharmacologically manipulate levels of the neurotransmitter? serotonin using ATD. Observation of systematic shifts in mood, behavioral preferences, or sensitivity? to reward outcomes would have profound implications for understanding phenotypic variation in? behavior associated with conditions such as depression, addiction, and anxiety syndromes. (4) We? will evaluate the effects of mood changes upon the neural processing of emotional and rewarding? stimuli. A common consequence of depression is anhedonia, or the inability to derive pleasure (or? other emotional reaction) from normally rewarding stimuli. We will use procedures developed in the? current period to manipulate mood state over short time intervals, and we will investigate how? transient negative mood influences activation in brain systems that process emotional and rewarding? stimuli.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Specialized Center (P50)
Project #
5P50MH060451-07
Application #
7478382
Study Section
Special Emphasis Panel (ZMH1)
Project Start
2007-08-01
Project End
2011-07-31
Budget Start
2007-08-01
Budget End
2008-07-31
Support Year
7
Fiscal Year
2007
Total Cost
$248,866
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Petyuk, Vladislav A; Chang, Rui; Ramirez-Restrepo, Manuel et al. (2018) The human brainome: network analysis identifies HSPA2 as a novel Alzheimer’s disease target. Brain 141:2721-2739
Sims, Rebecca (see original citation for additional authors) (2017) Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nat Genet 49:1373-1384
Jun, Gyungah R; Chung, Jaeyoon; Mez, Jesse et al. (2017) Transethnic genome-wide scan identifies novel Alzheimer's disease loci. Alzheimers Dement 13:727-738
Hohman, Timothy J; Bush, William S; Jiang, Lan et al. (2016) Discovery of gene-gene interactions across multiple independent data sets of late onset Alzheimer disease from the Alzheimer Disease Genetics Consortium. Neurobiol Aging 38:141-150
Jun, G; Ibrahim-Verbaas, C A; Vronskaya, M et al. (2016) A novel Alzheimer disease locus located near the gene encoding tau protein. Mol Psychiatry 21:108-17
Jacobsen, Jacob Pr; Rudder, Meghan L; Roberts, Wendy et al. (2016) SSRI Augmentation by 5-Hydroxytryptophan Slow Release: Mouse Pharmacodynamic Proof of Concept. Neuropsychopharmacology 41:2324-34
Ebbert, Mark T W; Boehme, Kevin L; Wadsworth, Mark E et al. (2016) Interaction between variants in CLU and MS4A4E modulates Alzheimer's disease risk. Alzheimers Dement 12:121-129
Hohman, Timothy J; Cooke-Bailey, Jessica N; Reitz, Christiane et al. (2016) Global and local ancestry in African-Americans: Implications for Alzheimer's disease risk. Alzheimers Dement 12:233-43
Saha, Sayoni; Hatch, Daniel J; Hayden, Kathleen M et al. (2016) Appetite and Weight Loss Symptoms in Late-Life Depression Predict Dementia Outcomes. Am J Geriatr Psychiatry 24:870-8
Jacobsen, Jacob P R; Krystal, Andrew D; Krishnan, K Ranga R et al. (2016) Adjunctive 5-Hydroxytryptophan Slow-Release for Treatment-Resistant Depression: Clinical and Preclinical Rationale. Trends Pharmacol Sci 37:933-944

Showing the most recent 10 out of 250 publications